ArticleFuture science OA2025
Adverse predictive value of ASPM on lung adenocarcinoma overall survival depended on chemotherapy status.
Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Identification and validation of selenium metabolism-related genes in lung adenocarcinoma prognosis using bioinformatics analysis.Frontiers in genetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTranscriptome and proteome analyses may yield inconsistent predictions regarding tumor prognosis. The clinical and pathological significance of ASPM expression in lung adenocarcinoma (LUAD) remains unclear. This study investigates the expression and prognostic value of ASPM, focusing on its role in chemotherapy outcomes.
methodsWe analyzed the prognostic relevance of ASPM using bioinformatics, immunohistochemical staining of LUAD tissue microarrays, and proteomics data. Further, in vitro experiments were conducted to evaluate the effects of ASPM overexpression on cell proliferation and sensitivity to cisplatin.
resultsBioinformatics analysis revealed that ASPM's prognostic significance differed between transcriptomic and proteomic datasets. Immunohistochemistry showed that high ASPM expression predicted improved overall survival only in LUAD patients undergoing chemotherapy, not in those without. Proteomics analysis identified ASPM-related signatures enriched in cell cycle and mitosis pathways. In vitro, ASPM overexpression promoted tumor cell proliferation and enhanced cisplatin-induced cytotoxicity.
conclusionASPM exhibits a dual role in LUAD prognosis, acting as a marker for improved chemotherapy outcomes while promoting tumor proliferation. These findings underscore ASPM's potential as a therapeutic target and predictive marker for personalized treatment in LUAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.